Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients - Wikidata - awgldk - TriplyDB

Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients

Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients

http://www.wikidata.org/entity/Q34316522

about

Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy The relationship between diabetes and colorectal cancer prognosis: A meta-analysis based on the cohort studies Genetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma.Prioritizing cancer therapeutic small molecules by integrating multiple OMICS datasets.Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients.Insulin-like growth factor-1 signaling in renal cell carcinoma A novel long noncoding RNA IRAIN regulates cell proliferation in non small cell lung cancer.Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.Biomarker-based selection of therapy for colorectal cancer.Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer.Association of IGF1R polymorphisms with the development of HBV-related hepatocellular carcinoma.Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy.Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen.Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.Association of insulin-like growth factor-I receptor polymorphism with colorectal cancer development.

P2860

Q26766535-72F9BED3-ADBC-4636-90C1-D6A92982BC91 Q26777125-EDC27C29-88AD-4088-9002-291E564C7B51 Q33579966-71065F66-49C7-4168-902F-8580F5D3B5A4 Q33779432-E56662AB-E2AE-4542-8036-111DA10448E8 Q34392085-60E32730-45E5-4B0C-9EE5-B3943EDE13A4 Q35583697-9A87E9CB-AA56-4E67-9908-4D27CBC5CA97 Q35637857-7A597F15-9644-4944-99D5-33466108C363 Q35948040-9B30D353-C42C-4FEF-87BB-50D5F32FA5CE Q36074111-CD3B1BCE-178D-4D10-AD73-F5D419022F9E Q36375083-40B6BB47-1A88-43C5-8F05-BC3FAAE1B8BA Q36433403-0175929B-2502-4D77-AC67-7925BDE27262 Q37327707-AFF4982A-A1D4-4B69-BBE5-D505CD166047 Q37886995-1A6F6C9F-D5A8-449B-8F84-0D8F786F4F5B Q38021921-29B0B2A0-8266-41D0-83EC-38E472C5D50A Q38219290-193AD6C2-888E-44D1-87B2-9EBB09C55D0F Q38399478-6EDAA8A6-118F-4E09-BBB7-F6D9504DABC7 Q42218166-01190DA1-A0B4-4423-80BE-B9B4486B4394 Q43509391-4BECF1B0-3F9A-4290-AB9C-2D67AC633600 Q46098680-12A20310-22B4-4485-802F-92BB25773640 Q46300809-13364D64-45EE-47A2-8B0C-DD1A5C0F3E4B Q54192785-0DA1E167-62BC-4073-A92A-B76C57180321

P2860

Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients

http://www.wikidata.org/entity/Q34316522

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Germline polymorphisms in gene ...... n wild-type KRAS mCRC patients

@ast

Germline polymorphisms in gene ...... n wild-type KRAS mCRC patients

@en

Germline polymorphisms in gene ...... n wild-type KRAS mCRC patients

@nl

type

label

Germline polymorphisms in gene ...... n wild-type KRAS mCRC patients

@ast

Germline polymorphisms in gene ...... n wild-type KRAS mCRC patients

@en

Germline polymorphisms in gene ...... n wild-type KRAS mCRC patients

@nl

prefLabel

Germline polymorphisms in gene ...... n wild-type KRAS mCRC patients

@ast

Germline polymorphisms in gene ...... n wild-type KRAS mCRC patients

@en

Germline polymorphisms in gene ...... n wild-type KRAS mCRC patients

@nl

P1433

Q34316522-4626373C-04FE-4792-A560-157999C5999A

P1476

Q34316522-C81627CB-0954-4BAB-9FB9-FAD5C26534C2

P2093

Q34316522-10F3F775-51F8-469C-860D-9A387C11EDC5

Q34316522-13D300BE-2131-4164-928E-1FC28054EB8C

Q34316522-1664F951-3E21-477D-932B-77F585E01151

Q34316522-439537D0-89F6-4384-98FD-CFB76A4CB30B

Q34316522-522370E9-5980-491B-9A10-D9A36AA02A7A

Q34316522-6FE77781-817B-48BB-B52C-4FD1EACA2B02

Q34316522-7D06C845-9A95-4368-A340-A674DE4A0BB2

Q34316522-810FE28A-4488-44C1-95C5-AC29C4E2426D

Q34316522-83FECC62-4CA3-4435-B6E8-D9C23E06582E

Q34316522-95DAA47F-C677-4FFA-A3B2-02A077893CA3

P2860

Q34316522-01624498-56CE-4553-8B3D-287CFA1B143B

Q34316522-0B8609D5-B864-4E8A-9A54-828A28FE956A

Q34316522-0BF1824B-1CCA-4183-9F44-FCCD7534C099

Q34316522-0C1D43B8-3E37-473E-9EBB-A2EE3DA6AA05

Q34316522-2449C719-F685-449B-8528-2C2695CF561A

Q34316522-27D54667-8542-4F5B-81AC-FF5E65612A34

Q34316522-29045019-2C44-44FB-A3B3-988C14C21FB6

Q34316522-31E8A227-84DE-411C-8166-FB2E4C0D7CE7

Q34316522-4A80CBAE-2158-4C6D-B598-1ECD6813FD58

Q34316522-4BF25A3A-B734-4848-A3D6-23D07FB76E76

P304

Q34316522-3762881B-87D3-4FDC-9689-F768498747C1

P31

Q34316522-1DC22E65-FE87-444D-ADCC-8B9C26E29C72

P356

Q34316522-9AFAE5CA-D991-47AA-B428-98B7B5DAA67A

P407

Q34316522-A9084CA7-620C-40BD-A22F-DF686196A24D

P433

Q34316522-12632458-5AF3-482A-A4B2-0E8ABA8B644E

P478

Q34316522-811A61B7-E4C8-484C-BC69-E9F862540ABA

P50

Q34316522-CB30C9FE-012C-4008-8BAF-F3B2CBEF3C7F

P577

Q34316522-7B7AA590-087A-40F2-8EB2-ED69520636E9

P5875

Q34316522-88FD6B33-909D-4FDF-9377-1EBD015434E1

P698

Q34316522-10E24476-F8AD-42F9-A3CD-2373511B7D98

P921

Q34316522-3D3C3621-5DD6-401D-9F30-C649FF20FC6E

Q34316522-AD138404-EA5D-46CC-BFEB-2A0C2450310F

P932

Q34316522-BE1A8CBA-9B6E-41CE-BE50-1923735C56CE

P356

1078-0432.CCR-10-2092

P1433

Clinical Cancer Research

P1476

Germline polymorphisms in gene ...... n wild-type KRAS mCRC patients

@en

P2093

Alexandra Pohl

http://www.w3.org/2001/XMLSchema#string

Armin Gerger

http://www.w3.org/2001/XMLSchema#string

Christiane Langer

http://www.w3.org/2001/XMLSchema#string

David J Mauro

http://www.w3.org/2001/XMLSchema#string

Dongyun Yang

http://www.w3.org/2001/XMLSchema#string

Eric K Rowinsky

http://www.w3.org/2001/XMLSchema#string

Peter M Wilson

http://www.w3.org/2001/XMLSchema#string

Pierre Bohanes

http://www.w3.org/2001/XMLSchema#string

Thomas Winder

http://www.w3.org/2001/XMLSchema#string

Wu Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Cetuximab for the treatment of colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Cancer statistics, 2009

Genetic variation in insulin-like growth factors and brain tumor risk.

IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).

Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer.

P304

5591-5602

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-2092

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Heinz-Josef Lenz

P577

2010-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47384354

http://www.w3.org/2001/XMLSchema#string

P698

20935157

http://www.w3.org/2001/XMLSchema#string

P921

P932

2982939

http://www.w3.org/2001/XMLSchema#string